drugset / Trial / NCT04327206

BCG Vaccination to Protect Healthcare Workers Against COVID-19

NCT04327206 ↗

RandomizedParallel-groupDouble-blindPrevention

Summary

Phase III, two-group multicentre, randomised controlled trial in up to 10 078 healthcare workers to determine if BCG vaccination reduces the incidence and severity of COVID-19 during the 2020 pandemic.

Timeline

Start
2020-03-30
Primary completion
2021-11-10
Completion
2022-05-27

Outcome

Missed primary endpoint

paper The estimated risk of symptomatic Covid-19 by 6 months was 14.7% in the BCG group and 12.3% in the placebo group PMID 37099341 ↗

paper Vaccination with BCG-Denmark did not result in a lower risk of Covid-19 among health care workers than placebo. PMID 37099341 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject BCG vaccine Vaccine 0.1 ml Intrathecal